Antibody Engineering & Therapeutics
The Antibody Engineering & Therapeutics event, held December 13-16, 2023 at Marriott Marquis San Diego (Booth #405), will feature presentations on cutting-edge antibody research including neurodegenerative diseases, tumor microenvironment, bi-specifics, ADCs, and immuno-oncology, highlighted by a session on sequence and structure-based workflows for single-domain antibody diversity and developability assessments using Geneious Biologics tools, presented by Dr. Vinodh Kurella of Takeda and Dr. Monica Watson of Dotmatics.
Event Details
- Event: Antibody Engineering & Therapeutics
- Date: December 13-16, 2023
- Location: Marriott Marquis San Diego, Booth #405
Join us at the Antibody Engineering & Therapeutics event to explore the latest science and research on antibody engineering, design, and selection. The event will cover critical topics including:
- Neurodegenerative Diseases
- Tumor Microenvironment in Antibody Therapy
- Antibody Immune Agonist
- Bi-Specifics
- ADCs (Antibody-Drug Conjugates)
- Protein-Based Degraders
- Immuno-oncology
- T-Cells
- VHH (single-domain antibodies)
- And much more
Presentation:
Antibody Sequence and Structure-based Workflows for Diversity and Developability Assessments
This presentation will walk through sequence and structure-guided analyses of sdAbs (single-domain antibodies) from diverse public sources using tools such as Geneious Biologics. It will include clustering and visualizations of sdAbs based on CDR-H3 diversity and developability assessments, as well as a brief overview of the potential for AI to direct antibody engineering efforts.
Speakers include:
- Vinodh Kurella, PhD
Senior Scientist, Takeda - Monica Watson, PhD
Field Application Scientist, Geneious Biologics, Dotmatics
Related
Dotmatics at Antibody Engineering & Therapeutics 2024
Dotmatics will exhibit at the Antibody Engineering & Therapeutics Conference from December 15-18, 2024, at the Marriott Marquis San Diego Marina (booth 313), featuring a presentation by Christian Olsen on December 16 about how Geneious Luma enhances therapeutic antibody engineering through adaptive workflows and data aggregation.
AE&T 2025: Full-Stack AI for Antibody Discovery
AE&T 2025 marked a pivotal shift in antibody R&D where AI-native, full-stack discovery systems seamlessly integrated in vitro, in vivo, and in silico workflows into a unified "lab-in-a-loop," emphasizing platform-level developability and overcoming fragmented data and workflows to transform complex protein designs into reliable therapeutics beyond oncology.
Multispecific Antibodies: Engineering the Non-natural
The article discusses the challenges and innovations in designing multispecific antibodies (MsAbs)—complex, non-natural biologics aimed at treating difficult diseases beyond the scope of traditional monoclonal antibodies—highlighting the need for advanced, flexible, AI-powered in silico design tools, such as those developed by Dotmatics and BioGlyph, that use building-block-based approaches to enable researchers to engineer novel biologic formats beyond rigid, predefined structures.
How Bispecific Antibodies Are Changing the Treatment of Complex Diseases
Bispecific antibodies, an advanced form of antibody therapeutics derived from the natural IgG structure, are revolutionizing the treatment of complex and treatment-resistant diseases by enabling simultaneous targeting of two different antigens, thereby expanding the possibilities of personalized immunotherapy in a rapidly growing market.
The Antibody Engineering & Therapeutics Conference
Dotmatics is sponsoring the Antibody Engineering & Therapeutics US 2022 conference on December 5 at Marriott Marquis San Diego, featuring innovations in antibody discovery and related fields, with a highlighted talk by Senior Solutions Architect Melanie Nelson on streamlining antibody discovery using Dotmatics Biology Solution from 1:15pm to 1:45pm PST at Booth 509.
Managing the Madness: Three Must-Dos for Tracking Multiformat Antibody R&D
The article discusses the increasing complexity of biologic antibody therapeutics, especially multiformat antibodies like bispecifics and antibody-drug conjugates, emphasizing the critical need for research teams to efficiently integrate diverse data types and collaborate across disciplines using unified software and dataflows to track and optimize these complex antibody designs.